益诺思 (688710)

1. Key Indicators

• Total Shares(W): 14097.96
• Circulating A-Shares(W): 9069.40
• Earnings Per Share(RMB): -0.1000
• Net Assets Per Share(RMB): 16.5773
• Operating Revenue(W RMB): 57068.81
• Total Profit(W RMB): 171.13
• **Net Profit Attributable to Parent(W RMB) **: -1478.81
• Net Profit Growth Rate(%): -111.14
• Weighted Return on Equity(%): -0.6200
• Operating Cash Flow Per Share(RMB): 0.1560
• Undistributed Profit Per Share(RMB): 3.3253
• Capital Reserve Per Share(RMB): 12.0125

---

2. Main Business

The main business covers:

• Professional provision of comprehensive R&D services primarily focused on non-clinical research services for biomedicine (CRO)

---

3. Company Basic Information

• Company Name: Shanghai Innostar Bio-tech Co., Ltd.
• Listing Date: 2024-09-03
• Industry: Research and Experimental Development
• Address: Room 106, No. 199 Guoshoujing Road, China (Shanghai) Pilot Free Trade Zone
• Website: https://www.innostarbio.com/
• Company Profile: The company was established through the overall transformation of Innostar Co., Ltd. into a joint stock company. On July 31, 2017, the State-owned Assets Supervision and Administration Commission of the State Council issued the "Reply on Issues Concerning the State-owned Equity Management of Shanghai Innostar Bio-tech Co., Ltd." (State-owned Property Rights [2017] No. 730) to China National Pharmaceutical Group, approving the transformation of Innostar Co., Ltd. into a joint stock company. It approved Innostar Co., Ltd. to convert the audited net assets of 56.6342 million yuan as of July 31, 2016 into the share capital of the joint stock company at a ratio of 1:0.882859, resulting in a total share capital of 50 million shares for the joint stock company after conversion. On September 8, 2017, the second interim shareholders' meeting of Innostar Co., Ltd. in 2017 reviewed and approved the transformation of the company from a limited company to a joint stock company. On September 28, 2017, the joint stock company held its founding meeting and first shareholders' meeting, reviewing and approving resolutions including the "Proposal on the Overall Transformation of Shanghai Innostar Bio-tech Co., Ltd. into Shanghai Innostar Bio-tech Co., Ltd." On November 1, 2017, Innostar completed the industrial and commercial change registration procedures for the aforementioned share reform and obtained the "Business License" issued by the Shanghai Administration for Industry and Commerce. Unified Social Credit Code: 91310000555907546T.

---

4. Top 10 Circulating Shareholders

Rank	Institution Name	Institution Type	Shares Held (W)	Percentage Held (%)
1	Shanghai Aopeng Enterprise Management Center (Limited Partnership)	General Legal Person	1741.24	19.20
2	Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd.	General Legal Person	1525.01	16.81
3	Advanced Manufacturing Industry Investment Fund (Limited Partnership)	General Legal Person	561.40	6.19
4	Shanghai Biopharmaceutical Public Technology Service Co., Ltd.	General Legal Person	550.92	6.07
5	Shanghai Pudong Emerging Industry Investment Co., Ltd.	General Legal Person	484.05	5.34
6	Shanghai Technology Venture Capital Co., Ltd.	General Legal Person	466.75	5.15
7	Conghua Huazhen Animal Farm (General Partnership)	General Legal Person	311.17	3.43
8	China Universal Healthcare Mixed Securities Investment Fund	Fund	112.15	1.24
9	ChinaAMC Stable Prosperity Flexible Allocation Mixed Securities Investment Fund	Fund	93.05	1.03
10	Caitong Asset Management Innovative Pharmaceuticals Mixed Securities Investment Fund Class A	Fund	6.54	0.07

---

5. Concept Sectors

• Immunotherapy
• CXO Concept
• Innovative Drugs
• Margin Trading & Securities Lending
• High P/E Ratio
• Two-Year New Stock
• Pension Fund
• Planned Reduction
• Small-Cap State-Owned Enterprise
• CSI Central State-Owned Enterprise
• Sci-Tech Innovation State-Owned Enterprise

---

Remarks

• Data update date: 2025-11-10
• Data source: Public market information